Trial · NCT07904910
Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study.
NCT07904910, Phase 3, Recruiting, Cairo University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study. Trials, record NCT07904910. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07904910
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study.
- NCT number
- NCT07904910
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 35 participants, estimated
- Lead sponsor
- Cairo University
- Conditions
- Vitiligo, Non-Segmental Vitiligo (NSV), Stable Vitiligo
- Interventions
- Crisaborole 2% topical ointment, tacrolimus 0.1%, Excimer Light therapy
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Facial Vitiligo Area Scoring Index (F-VASI) | Upon enrollment, at 12 weeks and at 24 weeks | The F-VASI is used specifically to quantify facial vitiligo involvement. The F-VASI score is calculated by multiplying the percentage of affected facial surface area by the degree of depigmentation for each facial site and summing these values across all facial sites. The F-VASI score ranged from 0 to 3, with lower scores indicating greater clinical improvement. |
| Primary | Vitiligo Extent Score for a Target Area (VESTA) | At 12 weeks and at 24 weeks | The score consists of: 1. Reference images for marginal repigmentation. 2. Reference images for perifollicular repigmentation. 3. A formula for calculating total repigmentation percentage. Total repigmentation percentage was defined as the sum of the fully repigmented area and perifollicular repigmentation in the remaining depigmented area. |
| Secondary | Time to onset of repigmentation | Since enrollment and throughout the treatment period till completion of the study | Time to onset of repigmentation is recorded. |
| Secondary | Vitiligo Impact Scale-22 (VIS-22) | At 12 weeks and at 24 weeks | Health-related quality of life is assessed using the Vitiligo Impact Scale-22 (VIS-22), a validated vitiligo-specific questionnaire composed of 22 items evaluating multiple psychosocial domains including anxiety, depression, self-confidence, social interactions, occupation, family relationships, and treatment-related concerns. The total score ranges from 0 to 66, with higher scores indicating greater impairment in quality of life. |
| Secondary | Patient Satisfaction | At 12 weeks and at 24 weeks | Patient satisfaction was assessed using a standardized five-point Likert scale as follows: 1. Very dissatisfied. 2. Dissatisfied. 3. Neutral. 4. Satisfied. 5. Very satisfied. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers14
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07904910
GET https://conductscience.org/api/trials/v1/NCT07904910/registered